{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:02:04Z","timestamp":1763596924380,"version":"3.45.0"},"reference-count":34,"publisher":"CSIRO Publishing","issue":"6","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Barriers to accessing opioid agonist treatment (OAT) extend beyond regulatory and clinical constraints, with logistical factors such as clinic location, limited prescriber availability, and transport challenges also playing a role. Despite this, transport-related barriers remain underexplored in the literature. This study aims to examine transport practices and driving histories among OAT clients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional survey across 15 public OAT clinics in New South Wales, Australia, was performed. Data were collected on participant demographics, sedating medication and illicit substance use, driving and other transport practices, and driving offence histories. Multivariate binary logistic regression examined factors associated with driving under the influence and reported driving offences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 482 clients surveyed, 86.5% reported using sedating medications or illicit drugs in the past month, and 40.3% had driven within that period. Fifty-seven participants reported driving after using a potentially impairing substance in the last month, who were more likely to receive OAT from a private clinic or pharmacy (aOR\u00a0=\u00a02.37, 95% CI\u00a0=\u00a01.14\u20134.92) and report past month illicit drug use (aOR\u00a0=\u00a06.55, 95% CI\u00a0=\u00a02.89\u201314.83). Participants with recent driving offences were more likely male (aOR\u00a0=\u00a01.87, 95% CI\u00a0=\u00a01.11\u20133.13) and to have a history of a driver licence suspension (aOR\u00a0=\u00a08.95, 95% CI\u00a0=\u00a05.38\u201314.90).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although substance use was common among participants, which could impact on driving safety, most did not report driving under the influence. A subset of clients who drive while impaired may present a public safety risk, and strategies to address this issue would be warranted. Ensuring appropriate access to OAT, including consideration of transport availability, remains a key component of equitable and safe treatment delivery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/py25035","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T23:58:51Z","timestamp":1763596731000},"source":"Crossref","is-referenced-by-count":0,"title":["Understanding issues of driving safety and transport utilisation among clients receiving opioid agonist treatment: a cross-sectional survey in New South Wales, Australia"],"prefix":"10.1071","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0339-0406","authenticated-orcid":true,"given":"Daniel T.","family":"Winter","sequence":"first","affiliation":[{"name":"ASpecialty of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia."},{"name":"BDrug and Alcohol Services, Northern Sydney Local Health District, Sydney, NSW, Australia."},{"name":"CEdith Collins Centre (Translational Research Centre in Alcohol Drugs and Toxicology), Sydney Local Health District, Camperdown, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren A.","family":"Monds","sequence":"additional","affiliation":[{"name":"ASpecialty of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia."},{"name":"BDrug and Alcohol Services, Northern Sydney Local Health District, Sydney, NSW, Australia."},{"name":"CEdith Collins Centre (Translational Research Centre in Alcohol Drugs and Toxicology), Sydney Local Health District, Camperdown, NSW, Australia."},{"name":"DNSW Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Sydney, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Lintzeris","sequence":"additional","affiliation":[{"name":"ASpecialty of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia."},{"name":"DNSW Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Sydney, NSW, Australia."},{"name":"EDrug and Alcohol Services, South Eastern Sydney Local Health District, Sydney, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin C.","family":"Riordan","sequence":"additional","affiliation":[{"name":"ASpecialty of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia."},{"name":"CEdith Collins Centre (Translational Research Centre in Alcohol Drugs and Toxicology), Sydney Local Health District, Camperdown, NSW, Australia."},{"name":"FCentre for Alcohol Policy Research, La Trobe University, Melbourne, Vic, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul S.","family":"Haber","sequence":"additional","affiliation":[{"name":"ASpecialty of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia."},{"name":"CEdith Collins Centre (Translational Research Centre in Alcohol Drugs and Toxicology), Sydney Local Health District, Camperdown, NSW, Australia."},{"name":"DNSW Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Sydney, NSW, Australia."},{"name":"GDrug Health Services, Sydney Local Health District, Camperdown, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn A.","family":"Day","sequence":"additional","affiliation":[{"name":"ASpecialty of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia."},{"name":"CEdith Collins Centre (Translational Research Centre in Alcohol Drugs and Toxicology), Sydney Local Health District, Camperdown, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"67","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2025111918584875600_R1","unstructured":"Australian Bureau of Statistics (2016) The Australian Statistical Geography Standard (ASGS) Remoteness Structure. Available at https:\/\/www.abs.gov.au\/websitedbs\/D3310114.nsf\/home\/remoteness%2Bstructure [accessed on January 2025]"},{"key":"2025111918584875600_R2","unstructured":"Australian Bureau of Statistics (2022) New South Wales 2021 census all persons QuickStats. Available at https:\/\/www.abs.gov.au\/census\/find-census-data\/quickstats\/2021\/1 [accessed on 17 January 2025]"},{"key":"2025111918584875600_R5","unstructured":"Australian Institute of Health and Welfare (2025) National opioid pharmacotherapy statistics annual data collection. (AIHW: Canberra)"},{"key":"2025111918584875600_R6","unstructured":"Austroads and National Transport Commission (2022) Assessing fitness to drive. Available at https:\/\/austroads.gov.au\/drivers-and-vehicles\/assessing-fitness-to-drive [accessed on 22 January 2025]"},{"issue":"1","key":"2025111918584875600_R7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder.","volume":"87","author":"Bell","year":"2020","journal-title":"Biological Psychiatry"},{"key":"2025111918584875600_R8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104255","article-title":"Trends in use of medicines for opioid agonist treatment in Australia, 2013\u20132022.","volume":"123","author":"Bharat","year":"2024","journal-title":"International Journal of Drug Policy"},{"issue":"5","key":"2025111918584875600_R9","doi-asserted-by":"publisher","first-page":"e673","DOI":"10.1016\/S2214-109X(23)00058-X","article-title":"Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review.","volume":"11","author":"Colledge-Frisby","year":"2023","journal-title":"The Lancet Global Health"},{"issue":"4","key":"2025111918584875600_R10","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/dar.14069","article-title":"Disparities in opioid agonist treatment accessibility for priority populations in New South Wales, Australia.","volume":"44","author":"Conigrave","year":"2025","journal-title":"Drug and Alcohol Review"},{"issue":"2","key":"2025111918584875600_R11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1046\/j.1360-0443.2003.00604.x","article-title":"Drug driving among injecting drug users in Sydney, Australia: prevalence, risk factors and risk perceptions.","volume":"99","author":"Darke","year":"2004","journal-title":"Addiction"},{"issue":"10208","key":"2025111918584875600_R12","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","article-title":"Global patterns of opioid use and dependence: harms to populations, interventions, and future action.","volume":"394","author":"Degenhardt","year":"2019","journal-title":"The Lancet"},{"key":"2025111918584875600_R13","doi-asserted-by":"crossref","unstructured":"Dobbs BM, Wodzin E, Vegega M (2005) Medical conditions and driving: a review of the literature (1960\u20132000). United States. Department of Transportation. National Highway Traffic Safety Administration.","DOI":"10.1037\/e729552011-001"},{"key":"2025111918584875600_R14","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-021-00535-y","article-title":"\u201cIt\u2019s like \u2018liquid handcuffs\u201d: the effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives.","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduction Journal"},{"issue":"3","key":"2025111918584875600_R15","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1080\/08897077.2014.924466","article-title":"Overview of substance use and treatment from Australia.","volume":"35","author":"Haber","year":"2014","journal-title":"Substance Use & Addiction Journal"},{"issue":"5","key":"2025111918584875600_R16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1071\/PY22269","article-title":"Identifying the most common barriers to opioid agonist treatment in an Australian setting.","volume":"29","author":"Hall","year":"2023","journal-title":"Australian Journal of Primary Health"},{"key":"2025111918584875600_R17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners.","volume":"95","author":"Harris","year":"2019","journal-title":"Journal of Biomedical Informatics"},{"key":"2025111918584875600_R19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.aap.2017.05.008","article-title":"Trends in reports of driving following illicit drug consumption among regular drug users in Australia, 2007\u20132013: has random roadside drug testing had a deterrent effect?","volume":"104","author":"Horyniak","year":"2017","journal-title":"Accident Analysis & Prevention"},{"issue":"1","key":"2025111918584875600_R21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1521-0391.2009.00007.x","article-title":"Benzodiazepines, methadone and buprenorphine: interactions and clinical management.","volume":"19","author":"Lintzeris","year":"2010","journal-title":"The American Journal on Addictions"},{"key":"2025111918584875600_R20"},{"issue":"2","key":"2025111918584875600_R22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.","volume":"2014","author":"Mattick","year":"2014","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"2025111918584875600_R23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1521-0391.2009.00005.x","article-title":"Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.","volume":"19","author":"McCance-Katz","year":"2010","journal-title":"The American Journal on Addictions"},{"key":"2025111918584875600_R18","unstructured":"NSW Health (2025) Drug and Alcohol Clinical Research and Improvement Network (DACRIN). Available at https:\/\/www.health.nsw.gov.au\/aod\/dacrin\/Pages\/default.aspx [accessed on 3 September 2025]"},{"key":"2025111918584875600_R24","unstructured":"NSW Ministry of Health (2018) NSW clinical guidelines: treatment of opioid dependence 2018. Available at https:\/\/www.health.nsw.gov.au\/aod\/Pages\/nsw-clinical-guidelines-opioid.aspx [accessed on 22 January 2025]"},{"key":"2025111918584875600_R25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugpo.2019.01.020","article-title":"Comparing Canadian and United States opioid agonist therapy policies.","volume":"74","author":"Priest","year":"2019","journal-title":"International Journal of Drug Policy"},{"key":"2025111918584875600_R26","doi-asserted-by":"publisher","DOI":"10.1186\/1747-597X-3-10","article-title":"Experience of road and other trauma by the opiate dependent patient: a survey report.","volume":"3","author":"Reece","year":"2008","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"2025111918584875600_R27","unstructured":"Road Transport Act 2013 (NSW) (2013) Section 5.1: alcohol and other drug use. Available at https:\/\/legislation.nsw.gov.au\/view\/html\/inforce\/current\/act-2013-018#ch.5-pt.5.1 [accessed on 16 May 2025]"},{"key":"2025111918584875600_R28","doi-asserted-by":"publisher","DOI":"10.1186\/1747-597X-8-19","article-title":"Driving and legal status of Spanish opioid-dependent patients.","volume":"8","author":"Roncero","year":"2013","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"issue":"6","key":"2025111918584875600_R29","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/dar.13250","article-title":"\u2018Very demanding. extremely rewarding\u2019: exploring the co-occurrence of burnout and engagement in alcohol and other drug workers.","volume":"40","author":"Skinner","year":"2021","journal-title":"Drug and Alcohol Review"},{"key":"2025111918584875600_R30","unstructured":"Transport for NSW (2024) Drugs & driving. Available at https:\/\/www.transport.nsw.gov.au\/roadsafety\/topics-tips\/drugs#Mobile_drug_testing [accessed on 21 February 2025]"},{"issue":"1","key":"2025111918584875600_R31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1172\/JCI134708","article-title":"Medications for opioid use disorders: clinical and pharmacological considerations.","volume":"130","author":"Volkow","year":"2020","journal-title":"The Journal of Clinical Investigation"},{"issue":"3","key":"2025111918584875600_R32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/09540120701192837","article-title":"Self reported risk behaviour among injecting drug users: self versus assisted questionnaire completion.","volume":"19","author":"White","year":"2007","journal-title":"AIDS Care"},{"issue":"6","key":"2025111918584875600_R33","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1111\/dar.13452","article-title":"A comment on participant reimbursement within Australian drug and alcohol research.","volume":"41","author":"Winter","year":"2022","journal-title":"Drug and Alcohol Reviews"},{"issue":"2","key":"2025111918584875600_R34","doi-asserted-by":"publisher","DOI":"10.1111\/ajr.70029","article-title":"Examining differences among opioid agonist treatment clients in regional and metropolitan settings of New South Wales, Australia.","volume":"33","author":"Winter","year":"2025","journal-title":"Australian Journal of Rural Health"},{"key":"2025111918584875600_R35","unstructured":"World Health Organization (2021) WHO model list of essential medicines 22nd list. Available at https:\/\/iris.who.int\/bitstream\/handle\/10665\/345533\/WHO-MHP-HPS-EML-2021.02-eng.pdf [accessed on 22 January 2025]"},{"issue":"5","key":"2025111918584875600_R36","first-page":"9","article-title":"A study of effects of multicollinearity in the multivariable analysis.","volume":"4","author":"Yoo","year":"2014","journal-title":"International Journal of Applied Science and Technology"}],"container-title":["Australian Journal of Primary Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/py\/article-pdf\/doi\/10.1071\/PY25035\/1823730\/py25035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/py\/article-pdf\/doi\/10.1071\/PY25035\/1823730\/py25035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T23:58:53Z","timestamp":1763596733000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/py\/article\/31\/6\/PY25035\/265831\/Understanding-issues-of-driving-safety-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1071\/py25035","relation":{},"ISSN":["1448-7527","1836-7399"],"issn-type":[{"value":"1448-7527","type":"print"},{"value":"1836-7399","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"article-number":"PY25035"}}